InsidersTradesSigma
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Browse the detailed record of transactions filed by Mehalick David, Chairman & CEO. Director active across 2 companies, notably Coeptis Therapeutics Inc.. Cumulatively, 4 reports have been published. Breakdown: 1 buy · 1 sell. Total volume traded: €3k. Activity tracked since 7 December 2023. The latest transaction was disclosed on 11 February 2026 (Levée d'options). Regulator: SEC (Form 4). The full history is free.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 of 4 declarations
David Mehalick is the CEO and President of Coeptis Therapeutics Inc. As the leader of the company, he is responsible for setting the strategic vision and overseeing daily operations. His role is crucial in guiding the company within the biotechnology sector, ensuring innovation and growth.